Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 1
- 10.1016/j.pbb.2011.09.010 · DOI · Paper page
Cited by
Items 501–600 of 1,640
Goes, F. S., Collado‐Torres, L., Zandi, P. P., Huuki-Myers, L. A., Tao, R., Jaffe, A. E., Pertea, G. M., Shin, J. H., Weinberger, D. R., Kleinman, J. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59115-4 · Cited by 48
Zhang, K., Wang, F., Yang, J., Wang, L., Pang, H., Su, G., Ma, J., Song, S., Xiong, Z., & Wu, C. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.08.031 · Cited by 35
“…antidepressants, such as selective serotonin reuptake inhibitors (SSRIs), have been widely used in clinic, these antidepressants are often accompanied with various side effects and were found effective in only 50% of the patients (Duman and Aghajanian, 2012; Jia et al., 2009; Li and Gao, 1996).”
BackgroundShah, A. P., Carreno, F. R., Wu, H., Chung, Y. A., & Frazer, A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.02.024 · Cited by 38
“As discussed (Shah et al., 2014), both VNS and ketamine modulate signaling pathways downstream of TrkB, such as the mammalian target of rapamycin (mTOR) pathway within the hippocampus indicated by increased phosphorylation of p70S6 kinase, in addition to AKT and ERK (Autry et al., 2011; Duman and Aghajanian, 2012; Car…”
BackgroundInfluentialLi, H., Chang, H., Song, X., Liu, W., Li, L., Wang, L., Yang, Y., Zhang, L., Li, W., Zhang, Y., et al. (2019) · Neuropsychopharmacology · doi:10.1038/s41386-019-0346-3 · Cited by 38
Yan, Y., Xu, X., Chen, R., Wu, S., Yang, Z. R., Wang, H., & Zhang, T. (2021) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2021.02.007 · Cited by 36
mTORC1 Signaling Pathway Mediates Chronic Stress-Induced Synapse Loss in the Hippocampus
Luo, Y., Ye, X., Fang, Y.-Z., Li, M., Xia, Z., Liu, J., Lin, X., Huang, Z., Zhu, X.-Q., Huang, J.-J., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.801234 · Cited by 39
“Emerging evidence demonstrates that synapse number and function are decreased in patients with MDD and bipolar disorders (BD) (Duman and Aghajanian, 2012; Kang et al., 2012).”
BackgroundJu, L.-S., Yang, J., Zhu, T., Liu, P., & Yang, J. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-03838-x · Cited by 36
“These features underlie the contributions of Narp to synaptic plasticity, which is considered to be one of the neurobiological mechanisms of depression [45].”
BackgroundHua, H., Huang, C., Liu, H., Xu, X., Xu, X., Wu, Z., Liu, C., Wang, Y. Y., & Yang, C. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109272 · Cited by 37
Nashed, M. G., Seidlitz, E. P., Frey, B. N., & Singh, G. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2015.07.040 · Cited by 41
Sun, X., Huang, W., Wang, J., Xu, R., Zhang, X., Zhou, J., Zhu, J., & Qian, Y. (2023) · Psychological Medicine · doi:10.1017/s0033291722003750 · Cited by 36
“Basic studies have documented that ketamine, a rapid antidepressant, can induce synaptogenesis and reverse synaptic deficits caused by chronic stress, highlighting the role of synaptic dysfunction in depression and its potential as a therapeutic target (Duman & Aghajanian, 2012).”
BackgroundYoon, S., Iqbal, H., Kim, S. M., & Jin, M. (2023) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.116 · Cited by 37
“In an animal model of chronic unpredictable restraint stress, MRI was used to indicate a reduced hippocampal volume, along with atrophy and loss of neurons (Duman and Aghajanian, 2012; Schoenfeld et al., 2017).”
BackgroundMethodPotential Roles of m6A and FTO in Synaptic Connectivity and Major Depressive Disorder
Mitsuhashi, H., & Nagy, C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076220 · Cited by 46
“There is evidence to suggest that MDD is associated with disrupted neuronal communication within and across regions of the brain associated with mood regulation and cognitive function [8].”
BackgroundIUPHAR review: Navigating the role of preclinical models in pain research
Karimi, S. A., Zahra, F. T., & Martin, L. J. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107073 · Cited by 38
Kuhn, M., Weidenauer, A., & Pezawas, L. (2014) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-139005 · Cited by 45
“With respect to MDD research, hippocampal volume reductions and functional alterations have repeatedly been found in patients (Bremner et al., 2000; Colla et al., 2007; Duman & Aghajanian, 2012; Eisch & Petrik, 2012; Masi & Brovedani, 2011).”
Anderson, R. M., Johnson, S. B., Lingg, R. T., Hinz, D. C., Romig‐Martin, S. A., & Radley, J. J. (2019) · Cerebral Cortex · doi:10.1093/cercor/bhz092 · Cited by 41
Furuyashiki, T., & Kitaoka, S. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12901 · Cited by 37
Intertwined associations between oxytocin, immune system and major depressive disorder
Jiang, J., Yang, M., Tian, M., Chen, Z., Xiao, L., & Gong, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114852 · Cited by 43
Li, Y., Yin, Q., Li, Q., Huo, A., Shen, T., Cao, J.-Q., Liu, C., Liu, T., Luo, W., & Cong, Q. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01058-x · Cited by 56
“In genetic animal models and human postmortem studies of depression, reductions in synapse number and decreased levels of synaptic signaling proteins are observed [9].”
BackgroundChen, H., Hong, L., Tong, S., Li, M., Sun, S., Xu, Y. Q., Liu, J., Feng, T., Li, Y., Lin, G., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04726-8 · Cited by 42
“According to the neuroplasticity hypothesis of depression [83, 84], chronic stress leads to sustained decreases in neuroprotective factors [e.”
BackgroundJia, Y., Song, N., Mao, R., Li, J., Zhang, Q., Huang, Y., Zhang, L., Han, H., Ding, Y., & Xu, L. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00325 · Cited by 33
Ankyrin-3 as a molecular marker of early-life stress and vulnerability to psychiatric disorders
Luoni, A., Massart, R., Nieratschker, V, Nemoda, Z., Blasi, G., Gilles, M., Witt, S. H., Suderman, M. J., Suomi, S. J., Porcelli, A., et al. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.211 · Cited by 33
Effect of ketamine combined with DHA on lipopolysaccharide-induced depression-like behavior in rats
Chang, D., Zhao, J., Zhang, X., Lian, H., Du, X., Yuan, R., Wen, Y., & Gao, L. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105788 · Cited by 33
da Rosa, P. B., Bettio, L. E. B., Neis, V. B., Moretti, M., Werle, I., Leal, R. B., & Rodrigues, A. L. S. (2019) · Purinergic Signalling · doi:10.1007/s11302-019-09681-2 · Cited by 33
Abdallah, C. G., Ahn, K.-H., Averill, L. A., Nemati, S., Averill, C. L., Fouda, S., Ranganathan, M., Morgan, P. T., D’Souza, D. C., Mathalon, D. H., et al. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00864-9 · Cited by 32
“Importantly, the mechanisms of action of ketamine and monoaminergic antidepressants are believed to converge at the level of synaptic connectivity [4, 29].”
BackgroundNing, L., Zhang, T., Chu, J., Qu, N., Li, L., Fang, Y., Shi, Y., Zeng, P. H., Cai, E., Wang, X., et al. (2017) · Molecular Neurobiology · doi:10.1007/s12035-016-0352-y · Cited by 34
“Studies in animals confirmed that chronic stress exposure causes atrophy and loss of neurons in the PFC and hippocampus, which contribute to the decreased volume of these brain regions in patients [30].”
BackgroundMolecular and cellular dissection of NMDA receptor subtypes as antidepressant targets
Lang, E., Mallien, A. S., Vasilescu, A.-N., Hefter, D., Luoni, A., Riva, M. A., Borgwardt, S., Sprengel, R., Lang, U. E., Gass, P., et al. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.08.012 · Cited by 33
“Over the last decades, the rapid and sustained antidepressant effect of ketamine in MDD has been labelled by some authors as ‘arguably the most important discovery in depression research in half a century’ (Duman and Aghajanian, 2012).”
Novaes, L. S., dos Santos, N. B., Dragunas, G., Perfetto, J. G., Leza, J. C., Scavone, C., & Munhoz, C. D. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.09.037 · Cited by 37
Interaction mechanisms between major depressive disorder and non-alcoholic fatty liver disease
Shao, Q., Wu, Y., Ji, J., Xu, T., Yu, Q., Ma, C., Liao, X., Cheng, F., & Wang, X. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.711835 · Cited by 32
“Therefore, the inflammatory mediator hypothesis (34) and a series of neural-related hypotheses, such as the neuroplasticity hypothesis/neurogenesis hypothesis (32), the neurotrophic factor (NF) hypothesis (35), the neuron regeneration hypothesis (36), and the neurosynaptic hypothesis, have been developed (37).”
BackgroundLi, W., Niu, L., Liu, Z., Xu, X., Shi, M., Zhang, Y., Deng, Y., He, J., Xu, Y., Wan, W., et al. (2021) · Neuroscience Letters · doi:10.1016/j.neulet.2021.136290 · Cited by 33
Guo, X.-F., Wang, X.-H., Fu, Y.-L., Meng, Q., Huang, B.-Y., Yang, R., Guo, Y., Du, Y.-R., Wang, X., Gao, Y., et al. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.05.004 · Cited by 32
Chen, H.-S., Wang, J., Li, H., Wang, X., Zhang, S.-Q., Deng, T., Li, Y.-K., Zou, R.-S., Wang, H.-J., Zhu, R., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn2496 · Cited by 32
“…with current major depressive disorder (MDD) and those at increased vulnerability to MDD ( 3 ), which are consistent with the studies of the postmortem human brain, that decreased expression of synapse-related genes and loss of synapses are observed in the PFC of patients with depression ( 4 , 5 ).”
Ye, Z., Wang, J., Fang, F., Wang, Y., Liu, Z., Shen, C., & Hu, Y. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.117355 · Cited by 37
Gong, Q., Li, W., Ali, T., Hu, Y., Mou, S., Liu, Z., Zheng, C., Gao, R., Li, A., Li, T., et al. (2023) · Translational Psychiatry · doi:10.1038/s41398-023-02646-5 · Cited by 34
“The accumulated evidence, including ours, shows protein synthesis is dysregulated in response to stimuli and contributes to altered synaptogenesis, which plays a crucial role in CNS disorders, including depression [13 – 15].”
BackgroundZhang, H., Xie, X., Xu, S., Wang, C., Sun, S., Song, X., Li, R., Li, N., Feng, Y., Duan, H., et al. (2024) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14661 · Cited by 40
From Stress to Synapse: The Neuronal Atrophy Pathway to Mood Dysregulation
Krasner, H., Ong, C. V., Hewitt, P., & Vida, T. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073219 · Cited by 42
“In mood disorders, dysregulated BDNF-TrkB signaling is observed, contributing to synaptic dysfunction and neuronal atrophy [176].”
Rapid antidepressant effects: moving right along
Martinowich, K., Jimenez, D. V., Zarate, C. A., & Manji, H. K. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.55 · Cited by 32
Glutamate system as target for development of novel antidepressants
Catena-Dell’Osso, M., Fagiolini, A. M., Rotella, F., Baroni, S., & Marazziti, D. (2013) · CNS Spectrums · doi:10.1017/s1092852912000971 · Cited by 33
Study on antidepressant activity of chiisanoside in mice
Bian, X., Liu, X., Liu, J., Zhao, Y. H., Li, H., Cai, E., Li, P., & Gao, Y. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.02.007 · Cited by 33
Amat-Foraster, M., Jensen, A. A., Plath, N., Herrik, K. F., Celada, P., & Artigas, F. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.04.022 · Cited by 35
“, 2016) and evoke longlasting biochemical/structural changes (Duman and Aghajanian, 2012; Li et al., 2010; Popp et al., 2016) that putatively could be involved in the long-lasting antidepressant effects of the drug (Mion and Villevieille, 2013).”
Liu, W., Yan, H., Zhou, D., Cai, X. M., Zhang, Y., Li, S., Li, H., Li, S., Zhou, D., Li, X., et al. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0675-3 · Cited by 36
Yao, Y., Xu, Y., Cai, Z., Liu, Q., Ma, Y., Li, A. N., Payne, T. J., & Li, M. D. (2020) · Psychological Medicine · doi:10.1017/s003329172000063x · Cited by 35
Ketamine improves short-term plasticity in depression by enhancing sensitivity to prediction errors
Sumner, R. L., McMillan, R., Spriggs, M. J., Campbell, D., Malpas, G., Maxwell, E., Deng, C., Hay, J., Ponton, R., Sundram, F., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.07.009 · Cited by 32
Effects of Ketamine on Learning and Memory in the Hippocampus of Rats through ERK, CREB, and Arc
Shi, M., Ding, J., Li, L., Bai, H., Li, X., Lan, L., Fan, H., & Gao, L. (2020) · Brain Sciences · doi:10.3390/brainsci11010027 · Cited by 35
“In clinical applications, studies have shown that ketamine is also a potential and effective antidepressant [22,23].”
BackgroundAugusto, E., Gonçalves, F. Q., Real, J. I., Silva, H. B. L., Pochmann, D., Silva, T. S., Matos, M., Gonçalves, N., Tomé, Â. R., Chen, J., et al. (2021) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105441 · Cited by 38
“…onset of neurodegeneration further argues for a prominent role of synaptic dysfunction in processes of activity-dependent neurodegeneration, as has been proposed in different neuropsychiatric conditions (see Duman and Aghajanian, 2012; Lepeta et al., 2016; Selkoe, 2002; Schirinzi et al., 2016).”
Farazi, N., Mahmoudi, J., Sadigh‐Eteghad, S., Farajdokht, F., & Rasta, S. H. (2021) · Lasers in Medical Science · doi:10.1007/s10103-021-03370-6 · Cited by 40
Zhang, H., Xue, X., Pan, J., Song, X., Chang, X., Mao, Q., Lu, Y., Zhao, H., Wang, Y., Chi, X., et al. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00519-x · Cited by 35
Liu, C., Chen, J., Liu, Y., Zhou, X., Zhang, M., Jiang, Y.-M., Ma, Q., Xue, Z., Zhao, Z., Li, X., et al. (2022) · Chinese Medicine · doi:10.1186/s13020-022-00621-8 · Cited by 35
“Recent clinical as well as basic research studies have linked the pathogenesis of depression with synaptic dysfunction in the prefrontal cortex and hippocampus [12], specifically within the hippocampal CA1 region.”
BackgroundCuccurazzu, B., Zamberletti, E., Nazzaro, C., Prini, P., Trusel, M., Grilli, M., Parolaro, D., Tonini, R., & Rubino, T. (2018) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy057 · Cited by 35
Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
Chen, B., Jin, K., Dong, J., Cheng, S., Kong, L., Hu, S., Chen, Z., & Lü, J. (2024) · Advanced Science · doi:10.1002/advs.202405354 · Cited by 43
Benefits and Challenges of Ultra-Fast, Short-Acting Psychedelics in the Treatment of Depression
Ramaekers, J. G., Reckweg, J. T., & Mason, N. L. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230890 · Cited by 37
Mechanisms of acupuncture in treating depression: a review
Ma, J., Yin, X., Cui, K., Wang, J., Li, W., & Xu, S. (2025) · Chinese Medicine · doi:10.1186/s13020-025-01080-7 · Cited by 42
“It is still necessary to further determine the neuronal and synaptic changes behind depression and explore the development of safer and more effective antidepressant therapy [60].”
Zhou, J., Liu, Z., Yu, J. H., Han, X., Fan, S., Shao, W., Chen, J., Qiao, R., & Xie, P. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv100 · Cited by 34
“This hippocampal dendritic or spine remodeling is dysregulated in stress-induced depression and stress resilience (Duman and Aghajanian, 2012; Gourley et al., 2013).”
BackgroundLiu, C., Gu, J.-Y., Han, J.-H., Yan, F.-L., Li, Y., Lv, T.-T., Zhao, L.-Q., Shao, Q.-J., Feng, Y.-Y., Zhang, X., et al. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.09.009 · Cited by 34
Park, S. W., Mansur, R. B., Lee, Y. L., Lee, J.-H., Seo, M. K., Choi, A. J., McIntyre, R. S., & Lee, J. G. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00756 · Cited by 36
Garel, N., McAnulty, C., Greenway, K. T., Lespérance, P., Miron, J., Rej, S., Richard‐Devantoy, S., & Jutras‐Aswad, D. (2022) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2022.109606 · Cited by 39
Li, Y., Fan, C., Wang, C., Wang, L., Yi, Y., Mao, X., Chen, X., Lan, T., Wang, W., & Yu, S. Y. (2022) · Science Advances · doi:10.1126/sciadv.add7063 · Cited by 28
“It has been reported that synaptic atrophy is observed in depressed patients and in animal models of depression and is positively correlated with the course and severity of depressive symptoms (4).”
BackgroundKetamine for Treatment-Resistant Depression
Zarate Jr, C. A., & Mathew, S. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-42925-0 · Cited by 38
Hou, Y., Wang, Y., Song, S., Zuo, Y., Zhang, H., Bai, C., Zhao, H., & Zhang, T. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113908 · Cited by 30
Li, H., Kawatake-Kuno, A., Inaba, H., Miyake, Y., Itoh, Y., Ueki, T., Oishi, N., Murai, T., Suzuki, T., & Uchida, S. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.004 · Cited by 36
Burgdorf, J. S., Zhang, X.-L., Colechio, E. M., Ghoreishi-Haack, N. S., Gross, A., Kroes, R. A., Stanton, P. K., & Moskal, J. R. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv101 · Cited by 34
“Both conventional and rapid-acting antidepressants facilitate synaptic plasticity, in part by activating growth factor signaling (Brunoni et al., 2008; Duman and Aghajanian, 2012).”
Chen, K.-T., Wu, C.-H., Tsai, M., Wu, Y.-C., Jou, M., Huang, C., & Wei, I. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.06.004 · Cited by 31
Kumar, A., Dogra, S., Sona, C., Umrao, D., Rashid, M., Singh, S. K., Wahajuddin, M., & Yadav, P. N. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.11.007 · Cited by 33
Amat-Foraster, M., Celada, P., Richter, U., Jensen, A. A., Plath, N., Artigas, F., & Herrik, K. F. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107745 · Cited by 34
“These effects are thus compatible with the glutamate hypothesis for fast-acting antidepressants, which suggests that a transient increase in glutamate release in the PFC is a key proximal event that leads to the activation of AMPA-Rs, thereby evoking a cascade of intracellular signaling pathways involved in synaptogen…”
ResultMolecular targets of psychedelic‐induced plasticity
Jaster, A. M., Revenga, M. D. L. F., & González‐Maeso, J. (2021) · Journal of Neurochemistry · doi:10.1111/jnc.15536 · Cited by 36
“…samples from subjects with depression and controls has provided evidence that mood disorders occur in conjunction with a reduction in the density of dendritic spines, particularly in the frontal cortex (Duman & Aghajanian, 2012; Liu & Aghajanian, 2008; Nestler et al., 2002; Russo & Nestler, 2013).”
BackgroundAsim, M., Wang, H., & Waris, A. (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102322 · Cited by 33
Asim, M., Wang, H., Chen, X., & He, J. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14422 · Cited by 35
Electroconvulsive seizure induces thrombospondin-1 in the adult rat hippocampus
Okada‐Tsuchioka, M., Segawa, M., Kajitani, N., Hisaoka‐Nakashima, K., Shibasaki, C., Morinobu, S., & Takebayashi, M. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.10.001 · Cited by 33
“Synaptic dysfunction has recently received attention for its involvement in mood disorders (Duman and Aghajanian, 2012).”
BackgroundSartim, A. G., Moreira, F. A., & Joca, S. R. L. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2016.10.031 · Cited by 33
Wei, M.-D., Wang, Y., Lu, K., Lv, B.-J., Wang, Y., & Chen, W. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112342 · Cited by 32
Li, Y., Dang, X., Chen, R., Wang, J., Li, S., Mitchell, B. L., Yao, Y.-G., Li, M., Li, T., Zhang, Z., et al. (2023) · doi:10.1101/2023.02.24.23286411 · Cited by 30
Magnetoencephalographic correlates of suicidal ideation in major depression
Gilbert, J. R., Ballard, E. D., Galiano, C. S., Nugent, A. C., & Zarate, C. A. (2020) · Biological Psychiatry: Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.11.011 · Cited by 28
“Thus, gamma can be considered a putative surrogate marker of neural, population-level excitationinhibition (E/I) balance (36) and synaptic potentiation (31), whose disruption can lead to synaptic loss, neuronal atrophy, and altered network-level connections (37).”
BackgroundThe Role of Glutamate Underlying Treatment-resistant Depression
Kim, J., Kim, T.-E., Lee, S., & Koo, J. W. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.22.1034 · Cited by 40
“In an early study, Duman and Aghajanian [77] suggested that ketamine rapidly and transiently increased glutamate transmission in”
BackgroundGe, Z., Hu, Y., Kan, W., Li, L., Xu, J., Zhang, Y., Zheng, N., Wang, G., & Du, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1625087 · Cited by 42
“Lipid dysregulation disrupts synaptic plasticity-the dynamic adaptability of neuronal connections-constituting a core pathological mechanism underlying cognitive dysfunction in depression (106).”
Wigner, P., Synowiec, E., Czarny, P. L., Bijak, M., Jóźwiak, P., Szemraj, J., Gruca, P., Papp, M., & Śliwiński, T. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15231 · Cited by 32
Neuronal Plasticity: Neuronal Organization is Associated with Neurological Disorders
Dhuriya, Y. K., & Sharma, D. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01555-2 · Cited by 32
Benefits of animal models to understand the pathophysiology of depressive disorders
Czéh, B., & Simon, M. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110049 · Cited by 30
“The “synaptogenic hypothesis of depression” postulates that dysfunctional synaptic transmission is a fundamental element of the pathophysiology of MDD (Duman et al., 2019, 2016; Duman and Aghajanian, 2012; Marsden, 2013).”
BackgroundDepression-Associated Gene Negr1-Fgfr2 Pathway Is Altered by Antidepressant Treatment
Carboni, L., Pischedda, F., Piccoli, G., Lauria, M., Musazzi, L., Popoli, M., Mathé, A. A., & Domenici, E. (2020) · Cells · doi:10.3390/cells9081818 · Cited by 30
“These findings have been complemented and expanded by observations in several preclinical models [69,70].”
BackgroundFriedland, K., Sillani, G., Schuwald, A. M., Stockburger, C., Koch, E., Nöldner, M., & Müller, W. E. (2020) · Pharmacopsychiatry · doi:10.1055/a-1293-8585 · Cited by 31
“To provide additional preclinical evidence for antidepressant effects of Silexan, we investigated the effects of Silexan on synaptic plasticity since improvement of synaptic plasticity seems to be the common final pathway for the mechanisms of action of most antidepressant drugs [25, 31, 32].”
BackgroundThe Role of Neurotrophic Factors in Pathophysiology of Major Depressive Disorder
Amidfar, M., Réus, G. Z., de Moura, A. B., Quevedo, J., & Kim, Y. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-981-33-6044-0_14 · Cited by 34
Ouyang, X., Wang, Z., Luo, M., Wang, M., Liu, X., Chen, J., Feng, J., Jia, J., & Wang, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-97758-7 · Cited by 37
Liu, S., Abdellaoui, A., Verweij, K. J. H., & van Wingen, G. A. (2023) · Advanced Science · doi:10.1002/advs.202205486 · Cited by 29
“control synaptic plasticity is disrupted in depression, resulting in destabilization and loss of synaptic connections in mood and emotion circuitry [50, 51].”
BackgroundMuzio, L., Brambilla, V., Calcaterra, L., D’Adamo, P., Martino, G., & Benedetti, F. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.063 · Cited by 32
“Depression is associated with decreased neuronal synapses and reduced size of brain regions which regulate mood and cognition, such as prefrontal cortex and hippocampus [22].”
The Hippocampus is a Critical Site Mediating Antidepressant-like Activity of Apelin-13 in Rats
Xiao, Z.-Y., Wang, B., Fu, W., Jin, X., You, Y., Tian, S., & Kuang, X. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.02.001 · Cited by 29
Real, J. I., Simões, A. P., Cunha, R. A., Ferreira, S. G., & Rial, D. (2018) · European Journal of Neuroscience · doi:10.1111/ejn.13912 · Cited by 28
“PFC function and associated behaviours are controlled by dopamine (Seamans & Yang, 2004), and its dysfunction is associated with psychiatric disorders such as schizophrenia, depression and attention deficit disorders (Duman & Aghajanian, 2012; Myers-Schulz & Koenigs, 2012).”
BackgroundGlucocorticoid receptor regulation of action selection and prefrontal cortical dendritic spines
Swanson, A. M., Shapiro, L. P., Whyte, A. J., & Gourley, S. L. (2013) · Communicative & Integrative Biology · doi:10.4161/cib.26068 · Cited by 34
The Molecular Basis of Insomnia: Implication for Therapeutic Approaches
Wang, Z., & Liu, J. (2016) · Drug Development Research · doi:10.1002/ddr.21338 · Cited by 32
Oña, G., Berrada, A., & Bouso, J. C. (2021) · Transcultural Psychiatry · doi:10.1177/13634615211038416 · Cited by 35
“…since atrophy in the neurons of the prefrontal cortex (PFC) plays a key role in mental and neurological disorders (Autry & Monteggia, 2012; Duman & Aghajanian, 2012; Duman et al., 2016; Qiao et al., 2016), and it can be counteracted by compounds capable of increasing neural plasticity in…”
BackgroundSun, Z., Jia, L., Shi, D., He, Y., Ren, Y., Yang, J., & Ma, X. (2021) · Behavioural Brain Research · doi:10.1016/j.bbr.2021.113709 · Cited by 34
“Among the several pathophysiological factors contributing to depression, loss of synaptic connections in the hippocampus plays a central role in the depressive phenotype and cognitive impairment [29-31].”
BackgroundJADE2 Is Essential for Hippocampal Synaptic Plasticity and Cognitive Functions in Mice
Fan, M., Liu, Y., Shang, Y., Xue, Y.-X., Liang, J., & Huang, Z. (2022) · Biological Psychiatry · doi:10.1016/j.biopsych.2022.05.021 · Cited by 28
Ketamine Users Have High Rates of Psychosis and/or Depression
Liang, H. J., Tang, K. L. A., Chan, F., Ungvari, G. S., & Tang, W. K. (2015) · Journal of Addictions Nursing · doi:10.1097/jan.0000000000000060 · Cited by 28
“Experimental studies have shown that ketamine rapidly induces synaptogenesis, reverses the synaptic deficits caused by chronic stress or depression, and produces antidepressant response within hours in patients who are resistant to typical antidepressants (Duman & Aghajanian, 2012).”
BackgroundXiang, J., Yan, S., Li, S., & Li, X. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005175 · Cited by 31
Stan, T. L., Alvarsson, A., Branzell, N., Sousa, V. C., & Svenningsson, P. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.39 · Cited by 29
Opler, L. A., Opler, M. G. A., & Arnsten, A. F. T. (2016) · CNS Spectrums · doi:10.1017/s1092852914000686 · Cited by 28
Yu, H., Yin, Z., Yang, S., Ma, S., & Qu, R. (2015) · Phytotherapy Research · doi:10.1002/ptr.5550 · Cited by 32
Repurposing Ketamine in Depression and Related Disorders: Can This Enigmatic Drug Achieve Success?
Carboni, E., Carta, A. R., Carboni, E., & Novelli, A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.657714 · Cited by 34
“BDNF and vascular endothelial growth factor induce the translation and synthesis of key synaptic proteins in synaptogenesis and maturation of dendritic spines, including GluA1 and postsynaptic density protein 95 (PSD95), via the TrkB/Flk-1 - mTORC1-signaling pathway (Duman and Aghajanian, 2012).”
BackgroundBleibel, L., Sokołowska, P., Henrykowska, G. A., Owczarek, J., & Wiktorowska‐Owczarek, A. (2025) · Pharmaceuticals · doi:10.3390/ph18060867 · Cited by 40
The faster-onset antidepressant effects of hypidone hydrochloride (YL-0919)
Sun, L., Zhang, L.-M., Liu, D., Xue, R., Liu, Y., Li, L., Guo, Y., Shang, C., Yao, J.-Q., Zhang, Y., et al. (2019) · Metabolic Brain Disease · doi:10.1007/s11011-019-00439-8 · Cited by 28
Arias, H. R., Targowska‐Duda, K. M., García‐Colunga, J., & Ortells, M. O. (2021) · Molecules · doi:10.3390/molecules26082149 · Cited by 32
Lopes, C. R., Oliveira, A., Gaspar, I. L., Rodrigues, M. S., Santos, J., Szabó, E. C., Silva, H. B. L., Tomé, Â. R., Canas, P. M., Agostinho, P. M., et al. (2023) · Biomolecules · doi:10.3390/biom13010106 · Cited by 36
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.